Literature DB >> 22000019

Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA.

Eva Kowalinski1, Thomas Lunardi, Andrew A McCarthy, Jade Louber, Joanna Brunel, Boyan Grigorov, Denis Gerlier, Stephen Cusack.   

Abstract

RIG-I is a key innate immune pattern-recognition receptor that triggers interferon expression upon detection of intracellular 5'triphosphate double-stranded RNA (5'ppp-dsRNA) of viral origin. RIG-I comprises N-terminal caspase activation and recruitment domains (CARDs), a DECH helicase, and a C-terminal domain (CTD). We present crystal structures of the ligand-free, autorepressed, and RNA-bound, activated states of RIG-I. Inactive RIG-I has an open conformation with the CARDs sequestered by a helical domain inserted between the two helicase moieties. ATP and dsRNA binding induce a major rearrangement to a closed conformation in which the helicase and CTD bind the blunt end 5'ppp-dsRNA with perfect complementarity but incompatibly with continued CARD binding. We propose that after initial binding of 5'ppp-dsRNA to the flexibly linked CTD, co-operative tight binding of ATP and RNA to the helicase domain liberates the CARDs for downstream signaling. These findings significantly advance our molecular understanding of the activation of innate immune signaling helicases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000019     DOI: 10.1016/j.cell.2011.09.039

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  320 in total

Review 1.  Activation and assembly of the inflammasomes through conserved protein domain families.

Authors:  Tengchuan Jin; Tsan Sam Xiao
Journal:  Apoptosis       Date:  2015-02       Impact factor: 4.677

2.  Structural insights into the activation of RIG-I, a nanosensor for viral RNAs.

Authors:  Qiu-Xing Jiang; Zhijian J Chen
Journal:  EMBO Rep       Date:  2011-12-23       Impact factor: 8.807

Review 3.  Highlights of the advances in basic immunology in 2011.

Authors:  Juan Liu; Shuxun Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2012-04-23       Impact factor: 11.530

4.  Structural Basis for a Novel Interaction between the NS1 Protein Derived from the 1918 Influenza Virus and RIG-I.

Authors:  Alexander S Jureka; Alex B Kleinpeter; Gabriel Cornilescu; Claudia C Cornilescu; Chad M Petit
Journal:  Structure       Date:  2015-09-10       Impact factor: 5.006

5.  Overexpression and purification of Dicer and accessory proteins for biochemical and structural studies.

Authors:  Niladri K Sinha; Brenda L Bass
Journal:  Methods       Date:  2017-07-16       Impact factor: 3.608

6.  Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.

Authors:  Chi-You Chang; Helene Minyi Liu; Ming-Fu Chang; Shin C Chang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Structural Insights into mitochondrial antiviral signaling protein (MAVS)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling.

Authors:  Zhubing Shi; Zhen Zhang; Zhenzhen Zhang; Yanyan Wang; Chuanchuan Li; Xin Wang; Feng He; Lina Sun; Shi Jiao; Weiyang Shi; Zhaocai Zhou
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

8.  MDA5 assembles into a polar helical filament on dsRNA.

Authors:  Ian C Berke; Xiong Yu; Yorgo Modis; Edward H Egelman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

9.  RIG-I Uses an ATPase-Powered Translocation-Throttling Mechanism for Kinetic Proofreading of RNAs and Oligomerization.

Authors:  Swapnil C Devarkar; Brandon Schweibenz; Chen Wang; Joseph Marcotrigiano; Smita S Patel
Journal:  Mol Cell       Date:  2018-09-27       Impact factor: 17.970

10.  Interferon Inducer IFI35 regulates RIG-I-mediated innate antiviral response through mutual antagonism with Influenza protein NS1.

Authors:  Hui Yang; Wendy Winkler; Xiaopeng Wu
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.